XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Thursday, Marketbeat reports. They presently have a $49.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 45.92% from the company’s current price.
XOMA has been the topic of a number of other reports. TheStreet upgraded shares of XOMA from an “e+” rating to a “c-” rating in a research report on Wednesday, November 29th. Zacks Investment Research upgraded shares of XOMA from a “sell” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Tuesday, October 17th. Finally, Wedbush reiterated a “buy” rating and issued a $33.00 price objective on shares of XOMA in a research report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $38.33.
Shares of XOMA (NASDAQ:XOMA) traded up $0.43 during trading on Thursday, hitting $33.58. 191,342 shares of the stock were exchanged, compared to its average volume of 177,730. The firm has a market cap of $269.98, a PE ratio of -4.68 and a beta of 3.17. XOMA has a fifty-two week low of $3.96 and a fifty-two week high of $37.25. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 3.53.
In related news, CFO Thomas M. Burns sold 6,983 shares of XOMA stock in a transaction on Monday, November 13th. The shares were sold at an average price of $30.99, for a total value of $216,403.17. Following the transaction, the chief financial officer now directly owns 13,538 shares in the company, valued at approximately $419,542.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Thomas M. Burns sold 22,222 shares of XOMA stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $28.69, for a total transaction of $637,549.18. Following the completion of the transaction, the senior vice president now owns 13,538 shares in the company, valued at $388,405.22. The disclosure for this sale can be found here. Over the last quarter, insiders sold 87,069 shares of company stock worth $2,517,993. 3.02% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of XOMA. EAM Investors LLC purchased a new stake in shares of XOMA during the 3rd quarter worth $835,000. OxFORD Asset Management LLP purchased a new stake in shares of XOMA during the 3rd quarter worth $543,000. Acadian Asset Management LLC purchased a new stake in shares of XOMA during the 4th quarter worth $152,000. Finally, Bank of Montreal Can purchased a new stake in shares of XOMA during the 4th quarter worth $138,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.
XOMA Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.